Prima BioMed (IMMP)
(Real Time Quote from BATS)
$1.87 USD
0.00 (0.00%)
Updated Aug 8, 2024 01:51 PM ET
4-Sell of 5 4
F Value F Growth A Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
IMMP 1.87 0.00(0.00%)
Will IMMP be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for IMMP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IMMP
Immutep (IMMP) Up as Combo Therapy Meets Carcinoma Study Goals
Prima BioMed (IMMP) Loses -34.84% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
IMMP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Immutep (IMMP) Up on Initial Data From Lung Cancer Study
Immutep (IMMP) Surges 65% on Upbeat Lung Cancer Study Data
Other News for IMMP
Immutep to Participate in Upcoming Investor Conferences
Immutep Advances LAG-3 Immunotherapy Trials
Immutep Quarterly Activities Report Q4 FY24
Immutep resports quarterly activities for Q4
Abbott, Integra LifeSciences And Other Big Stocks Moving Lower In Monday's Pre-Market Session